Mesoblast (MESO) Other Non-Current Liabilities (2015 - 2025)
Mesoblast's (MESO) quarterly Other Non-Current Liabilities came in at $14.2 million in Q4 2025, down 48.59% year-on-year from $27.6 million in Q4 2024, and up 147.59% quarter-over-quarter from $5.7 million in Q2 2025.
Mesoblast (MESO) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Mesoblast has disclosed Other Non-Current Liabilities across 11 years of filings, most recently posting $14.2 million for Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $14.2 million, down 48.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.2 million (down 48.59% YoY), and the FY2025 annual result was $5.7 million, down 46.1% from the prior year.
- Other Non-Current Liabilities came in at $14.2 million for Q4 2025 at Mesoblast, up from $5.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $27.6 million in Q4 2024 to a low of $2.2 million in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $17.7 million (2022), against an average of $15.6 million.
- Across the five-year window, Other Non-Current Liabilities surged 148.33% in 2023 and slumped 48.59% in 2025, its largest moves.
- Mesoblast's Other Non-Current Liabilities stood at $22.3 million in 2021, then slipped by 19.9% to $17.9 million in 2022, then decreased by 4.37% to $17.1 million in 2023, then soared by 61.47% to $27.6 million in 2024, then plunged by 48.59% to $14.2 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $14.2 million (Q4 2025), $5.7 million (Q2 2025), and $27.6 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.17 Mn |
| Jun 30, 2025 | 5.72 Mn |
| Dec 31, 2024 | 27.57 Mn |
| Jun 30, 2024 | 10.62 Mn |
| Dec 31, 2023 | 17.07 Mn |
| Jun 30, 2023 | 5.43 Mn |
| Mar 31, 2023 | 17.58 Mn |
| Dec 31, 2022 | 17.85 Mn |
| Sep 30, 2022 | 19.46 Mn |
| Jun 30, 2022 | 2.19 Mn |
| Mar 31, 2022 | 20.22 Mn |
| Dec 31, 2021 | 22.29 Mn |
| Sep 30, 2021 | 19.65 Mn |
| Mar 31, 2021 | 18.76 Mn |
| Dec 31, 2020 | 19.44 Mn |
| Sep 30, 2020 | 22.22 Mn |
| Jun 30, 2020 | 29.20 Mn |
| Mar 31, 2020 | 28.11 Mn |
| Dec 31, 2019 | 30.38 Mn |
| Sep 30, 2019 | 30.56 Mn |